Clinical Trial Goal
To find out:
- The highest dose of teclistamab that's safe to give
- If teclistamab is safe and works well to treat multiple myeloma that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years old or older
- Have multiple myeloma that has relapsed or is refractory
- Do not have any of the following:
- Amyloidosis
- Plasma cell leukemia
- POEMS Syndrome
- Waldensrom's macroglobulinemia
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Teclistamab is a bispecific antibody that targets BCMA and CD3 on certain cells.
You’ll get:
You’ll get:
- Teclistamab – Given as intravenous (IV) infusions. The dose you'll get depends on when you start the trial and how safe it has been
You'll have biopsies and/or scans to see how well the treatment is working.
The Food and Drug Administration (FDA) has approved all of the drugs used in this trial.
Contacts
Jessica Vandermark, (203) 354-7215, vandermarkj@themmrf.org
Mercedes Martillo, martillom@themmrf.org
Locations
Sponsors
lead: Multiple Myeloma Research Consortium
